High affinity sirp-alpha reagents and methods of using
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsAaron Michael Ring, Kenan Christopher Garcia, Kipp Andrew Weiskopf, Aron M. Levin, Irving L. Weissman
Life of this patent
Estimating the term…
Abstract
High affinity SIRP-α reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRPα reagent, which blocks the physiological binding interaction between SIRPα and its ligand CD47.
Claims26
A high affinity SIRPα polypeptide, wherein the polypeptide lacks the SIRPα transmembrane domain and comprises at least one amino acid modification relative to the wild-type SIRPα sequence, and wherein the amino acid modification increases the affinity of the SIRPα polypeptide binding to CD47.
Dependencies are inferred from the claim text.